Vijaypd Ceutical IPO Subscription Status

NSE SME
Minimum investment
₹ 2,80,000 8000 shares
View IPO details

Data sourced from NSE · Compiled by IPO Ji · IPO subscription data last updated

Total 1.43x·QIB 0.00x·NII 1.97x·Individual 0.89x

Individual allotment likelyhigh allotment chance

Individual is currently subscribed 0.89× by applications, so individual applicants are likely to receive a full allotment, subject to the issue achieving its minimum subscription.

Vijaypd Ceutical Limited SME IPO was subscribed 1.43x in total when bidding closed on Oct 1, 2025, with 0x in the QIB category, 1.97x in NII, 0.89x in individual across NSE. The issue is oversubscribed, indicating healthy demand across investor categories. The issue ran from Sep 29, 2025 to Oct 1, 2025 at a price band of ₹35–₹35 per share. Allotment was finalised on Oct 3, 2025.

QIB0.00xNII1.97xIndividual0.89xTotal1.43x1x
Times subscribed by category against the 1× fully-subscribed line (bars capped at 10×).
Advertisement
Advertisement

Subscription Details (No. of Shares)

Category Offer Applied Times
NIIs 2608000 5128000 1.97
Individual 2608000 2320000 0.89
Total 5216000 7448000 1.43
Total Applications401 approx.

Application Wise Breakup (Approx.)

Category Reserve Applied Times
NIIs 0 111 0
Individual 326 290 0.89
Total Applications401 approx.

Subscription Details (In Crores)

Category Offered Demand Times
NIIs 9.13 17.95 1.97
Individual 9.13 8.12 0.89
TOTAL 18.26 26.07 1.43

Day-wise subscription

Total subscription trend0.59x to 1.37x+0.78x
0.00x1.37x1x0.59xDay 10.98xDay 21.37xDay 3
As on QIB Individual Total
Day 1
29 Sep 2025
6:00 PM
1.10x 0.08x 0.59x
Day 2
30 Sep 2025
6:00 PM
1.67x 0.29x 0.98x
Day 3
1 Oct 2025
6:00 PM
1.86x 0.89x 1.37x

Subscription by number of applications

Anticipated subscription based on the number of applications received (an alternative to the shares-based figures above), sourced from NSE.

CategoryTimes (by applications)
bHNI0.00x
sHNI0.00x
Individual0.89x
Total applications~401

What this means for allotment & listing

Because Vijaypd Ceutical closed oversubscribed, applicants were not guaranteed full allotment. In oversubscribed issues, shares are allotted according to the applicable category and exchange rules, so applicants are not guaranteed full allotment once an issue is oversubscribed. The number of times each category is subscribed is one indicator of demand, alongside the company's fundamentals and the broader market.

A high subscription figure reflects strong demand but does not guarantee a premium listing, and a low figure does not guarantee a discount. This page is for information only and is not investment advice. Investors should read the company's prospectus and consult a SEBI-registered adviser before making any decision.

Listed at NSE SME · Registrar: Kfin Technologies Ltd. · Bidding data sourced from the NSE public-issue platform under SEBI ICDR regulations.

IPO subscription status shows how many times an issue has been applied for, compared with the shares on offer, broken down by Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII), and the Retail or SME Individual Investor category. A figure of "2x" means investors applied for twice the shares available. See how IPO subscription works and track all live IPOs →

Vijaypd Ceutical IPO subscription FAQs

Vijaypd Ceutical Limited IPO was subscribed 1.43x at close on Oct 1, 2025, with 0x in QIB, 1.97x in NII, 0.89x in individual.

Yes. Vijaypd Ceutical IPO was subscribed 1.43x, meaning investors applied for 1.43x the number of shares on offer.

The Vijaypd Ceutical IPO allotment was finalised on Oct 3, 2025. You can check your allotment status by PAN or application number on the registrar's website or on IPO Ji.

Vijaypd Ceutical IPO has a price band of ₹35–₹35 per share, with a minimum individual investor application of ₹2,80,000 for 8000 shares.

It means investors have applied for X times the number of shares the company is offering. For example, 5x means demand was five times the shares available. A figure above 1x is called oversubscription; below 1x is undersubscription.

No. The higher an issue is oversubscribed, the lower each applicant’s chance of allotment. SME shares are allotted according to the applicable Individual Investor, NII and exchange rules, so oversubscription does not guarantee full allotment.

QIB covers qualified institutions. Under the current SME IPO framework, an Individual Investor applies for the minimum application size of two lots above ₹2 lakh, while applicants bidding for more than two lots are classified in the NII category. Each category has its own reserved portion and allotment rules.

IPO Ji updates subscription figures through the bidding day using data sourced from NSE. The "Last updated" time shown on the page reflects the most recent refresh.

Other live IPO subscriptions

Advertisement
Important Disclaimer

Data Source: The above information / data is sourced from National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) websites and is subject to change in real time. For latest information / data, please refer to the respective websites.

Purpose: The information / data provided herein is for informational purposes only and is provided by ipoji.com on "AS IS" and "AS AVAILABLE" basis and without warranty, express or implied.

Accuracy: ipoji.com does not warrant the accuracy, adequacy or completeness of the information you obtain through the above websites.

Liability: ipoji.com shall not be liable in any way for any discrepancies, errors, omissions, losses or damage. ipoji.com, including its affiliates and its directors, staff and employees, shall not be liable for any loss, damage of any kind, including but not limited to direct, indirect, punitive, exemplary, consequential damages and lost profits arising in any way out of the use of information / data obtained through the said websites.

User Responsibility: The recipient alone is fully responsible / liable for any decision made based on this information / data. All recipients, before relying on the said information, should do their own research and seek appropriate professional advice.